Home›Articles›One Drug, Three Approvals: Sacituzumab GovitecanArticleOne Drug, Three Approvals: Sacituzumab GovitecanArticlesConnectionsSourcesComments (0)Reader Challenges (0)ConnectionsArticle OnSacituzumab govitecan, Drugs and Medicinal Substances Well-attested SourcesSacituzumab govitecan (Wikipedia)History section, raw wikitext (action=raw) fetched 2026-09-21Quote, History section, raw wikitext (action=raw) fetched 2026-09-21Sacituzumab govitecan-hziy was approved based on the results of IMMU-132-01, a multicenter, single-arm clinical trial (NCT01631552) of 108 participants with metastatic triple-negative breast cancer who had received at least two prior treatments for metastatic diseaseView the SourceMedicine Atlas Original Articlestier 1Comments (0)No comments yet. Be the first to share a thought.Sign in to join the discussion.Reader Challenges (0)No disputes yet. Spotted an error or a better source? Open the first one.Sign in to dispute this or suggest a correction.